The Valley Hospital is now open at 4 Valley Health Plaza in Paramus. (You may need to use 650 Winters Avenue for GPS.) All emergency care is now being provided at this location. Emergency care is no longer available at our Ridgewood campus.
Clinical Trials
To view the clinical trials Valley currently has available, please use the search field or select a clinical specialty from the drop-down list below. Be sure to check back frequently, as we are always adding new studies.
For more information about any of our clinical trials, please email [email protected] or call 201-447-8453. (For cancer clinical trials, please call 201-634-5792.)
GLORIOSA
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA).
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Open and enrolling
GOG 3026
A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Closed to Enrollment, No Patients in Follow-Up
GOG 3035
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Open and enrolling
PRESERVE-004 (GOG-3081)
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)
Principal Investigator(s): Amanda J. Podolski, MD
Status: Open and enrolling